MicroRNA-34 family in cancers: role, mechanism, and therapeutic potential

J Fu, S Imani, MY Wu, RC Wu - Cancers, 2023 - mdpi.com
Simple Summary The dysregulation of the miR-34 family has been shown to play an
important role in tumorigenesis and cancer progression. In this review, we summarized the …

Prostate cancer and the cell cycle: focusing on the role of microRNAs

IM Elazab, OA El-Feky, EG Khedr, NE El-Ashmawy - Gene, 2024 - Elsevier
Prostate cancer is the most frequent solid tumor in terms of incidence and ranks second only
to lung cancer in terms of cancer mortality among men. It has a considerably high mortality …

Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises

W Li, Y Wang, X Liu, S Wu, M Wang… - International Journal of …, 2024 - mdpi.com
Prostate cancer (PCa) remains a common cancer with high mortality in men due to its
heterogeneity and the emergence of drug resistance. A critical factor contributing to its …

miRNA/epithelial-mesenchymal axis (EMT) axis as a key player in cancer progression and metastasis: A focus on gastric and bladder cancers

AS Sahib, A Fawzi, RS Zabibah, NA Koka, SA Khudair… - Cellular …, 2023 - Elsevier
The metastasis a major hallmark of tumors that its significant is not only related to the basic
research, but clinical investigations have revealed that majority of cancer deaths are due to …

[HTML][HTML] Bioinformatics and system biology approaches for identifying potential therapeutic targets for prostate cancer

MAR Ashik, MA Hossain, SA Rahman, MS Akter… - Informatics in Medicine …, 2024 - Elsevier
Prostate cancer (PCa) is the primary cause of cancer-related deaths among men, and its
incidence increases with age. Despite the availability of treatments, the high costs and …

The role of microRNAs in hepatocellular cancer: a narrative review focused on tumor microenvironment and drug resistance

A Tavakoli Pirzaman, A Alishah… - … in Cancer Research …, 2024 - journals.sagepub.com
Globally, hepatic cancer ranks fourth in terms of cancer-related mortality and is the sixth
most frequent kind of cancer. Around 80% of liver cancers are hepatocellular carcinomas …

Revolutionizing cancer therapy: nanoformulation of miRNA-34–enhancing delivery and efficacy for various cancer immunotherapies: a review

MP Fawzy, HAFM Hassan, NK Sedky, MS Nafie… - Nanoscale …, 2024 - pubs.rsc.org
Despite recent advancements in cancer therapies, challenges such as severe toxic effects,
non-selective targeting, resistance to chemotherapy and radiotherapy, and recurrence of …

Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent

AM Abdelaal, IS Sohal, SG Iyer, K Sudarshan… - … Therapy-Nucleic Acids, 2024 - cell.com
Use of tumor-suppressive microRNAs (miRNAs) as anti-cancer agents is hindered by the
lack of effective delivery vehicles, entrapment of the miRNA within endocytic compartments …

Drastic Synergy of Lovastatin and Antrodia camphorata Extract Combination against PC3 Androgen-Refractory Prostate Cancer Cells, Accompanied by AXL and …

CJ Yao, CL Chang, MH Hu, CH Liao, GM Lai, TJ Chiou… - Nutrients, 2023 - mdpi.com
Prostate cancer (PC) is the second most frequently diagnosed cancer and the fifth leading
cause of cancer-related death in males worldwide. Early-stage PC patients can benefit from …

Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises

W Li, Y Wang, X Liu, S Wu, M Wang, SG Turowski… - bioRxiv, 2023 - biorxiv.org
Prostate cancer (PCa) remains a common cancer with high mortality in men due to its
heterogeneity and the emergence of drug resistance. A critical factor contributing to its …